| Cost-effectiveness model | L-Sarcoma | Non-L-sarcoma | Trabectedin | Ifosfamide | Difference | Trabectedin | Ifosfamide | Difference |
| Costs (all discounted) | €44,879 | €24,797 | €20,082 | €27,497 | €22,799 | €4,698 | (i) Drug acquisition | €31,597 | €4,113 | €27,484 | €19,407 | €3,660 | €15,747 | (ii) Drug administration | €5,298 | €13,380 | −€8,082 | €3,646 | €11,941 | − €8,295 | (iii) Nonrelated costs | €6,866 | €5,464 | €1,402 | €3,325 | €5,357 | − €2,032 | (iv) Adverse events costs | €1,119 | €1,841 | −€722 | €1,119 | €1,841 | − €722 |
| Effectiveness | | | | | | | (i) QALYs, discounted | 1.025 | 0.773 | 0.251 | 0.516 | 0.781 | −0.265 | (ii) Preprogression LYs, undiscounted | 0.646 | 0.423 | 0.223 | 0.386 | 0.476 | −0.090 | (iii) Postprogression LYs, undiscounted | 0.902 | 0.758 | 0.144 | 0.371 | 0.694 | −0.323 | Cost-effectiveness ratios |
| (i) Costs per LY gained | €56,000 | Ifosfamide dominant | (ii) Costs per QALY gained | €80,000 | Ifosfamide dominant |
|
|